Bayer’s LYNKUET (elinzanetant) receives expanded authorization in Canada for breast cancer-related vasomotor symptoms Bayer Canada announced that Health Canada has expanded the market authorizat...
Takeaways: CDA‑AMC’s positive, conditional reimbursement recommendation for Nucala (mepolizumab) in adults with COPD and raised blood eosinophils who remain uncontrolled on ICS/LABA/LAMA triple therap...
Takeaways: GSK’s prefilled Shingrix syringe should improve operational convenience for clinics and pharmacies by removing the reconstitution step, which can reduce preparation time, ha...
Takeaways: Exdensur positions GSK as the first biologic in Canada with twice-yearly dosing for severe eosinophilic asthma, a major convenience advantage over existing IL‑4/5...
Takeaways Blenrep’s pCPA negotiations are an important step toward broader Canadian access to a new multiple myeloma option, especially because the drug is being positio...
Takeaways Bepirovirsen’s Canada filing signals a coming shift in the hepatitis B market from lifelong viral suppression to time‑limited “functional cure” regimens, which could reshape how p...
